Related Experiment Video
Updated: Jun 22, 2026
12:59
Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
Published on: July 5, 2017
Improved tolerance to sequential glucose loading (Staub-Traugott effect): size and mechanisms.
Sandra Bonuccelli1, Elza Muscelli, Amalia Gastaldelli
1Department of Internal Medicine, University of Pisa School of Medicine, Pisa, Italy.
Summary
The Staub-Traugott effect, or improved glucose tolerance after sequential glucose loads, is driven by enhanced glucose potentiation and better suppression of endogenous glucose release. These mechanisms improve day-to-day glycemic control in healthy individuals.
Area of Science:
- Endocrinology
- Metabolism
- Human Physiology
Background:
- The Staub-Traugott effect describes improved glucose tolerance following sequential glucose challenges.
- Understanding the underlying physiological mechanisms is crucial for managing glycemic exposure.
Purpose of the Study:
- To elucidate the mechanisms behind the Staub-Traugott effect in healthy volunteers.
- To investigate the roles of beta-cell function, glucose kinetics, and endogenous glucose production.
Main Methods:
- Two sequential oral glucose tolerance tests (OGTTs) were performed, with one study involving glucose clamping.
- beta-Cell function was assessed using mathematical modeling of C-peptide levels.
- Glucose kinetics were measured using a triple-tracer technique in a subgroup.
Main Results:
- The second OGTT showed significantly reduced glucose response (84% of the first) despite lower absolute insulin secretion.
- Glucose potentiation was significantly stronger during the second OGTT, indicating enhanced insulin secretion relative to glycemia.
- Stronger suppression of endogenous glucose production was observed during the second OGTT.
Conclusions:
- Enhanced glucose potentiation and improved suppression of endogenous glucose production are the primary mechanisms driving the Staub-Traugott effect.
- These findings contribute to understanding daily glycemic regulation and the body's adaptive responses to glucose challenges.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:26Glucose Absorption Into the Small Intestine
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and 'exit' via the...
01:02Glucose Homeostasis: Regulation of Blood Glucose
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...